Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE
Objective: to analyze the long term efficacy and tolerability of safinamide added as adjunctive therapy in a series of patients with Parkinson´s disease (PD) Background:…Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease
Objective: To compare Parkinson’s disease (PD) treatment practices by movement disorder (MD) specialists across a decade, and to determine the factors that influence drug choice…Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats
Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)
Objective: We compared the effects of safinamide on the urinary symptoms of Parkinson's disease with other therapies. Background: Urinary symptoms (US) are common, disabling and…Is safinamide helpful in multiple system atrophy?
Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?
Objective: After more than two years of clinical experience with safinamide we want to retrospectively review its utility as a levodopa saver in our Parkinson's…High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients
Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- Next Page »